Clinical Nephrology - IgA Nephropathy, Lupus Nephritis, Vasculitis

SP307

EFFICACY AND SAFETY OF TELMISARTAN, CLOPIDOGREL, AND LEFLUNOMIDE IN PATIENTS WITH IgA NEPHROPATHY – A MULTICENTRE, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND AND -DUMMY CONTROLLED CLINICAL TRIAL

Jie Wu1, Shuwei Duan1, Wenge Li1, Yaping Wang1, Wenhui Liu1, Jianrong Zhang1, Lide Lun1, Xuelei Li1, Chunhua Zhou1, Ying Zheng1, Shuwen Liu1, Yuanxing Xie1, Guangyan Cai1 and Xiaomei Chen1

1Department of Nephrology, State Key Laboratory of Kidney Disease Beijing China

Introduction and Aims: To evaluate the efficacy and safety of telmisartan combined with clopidogrel and/or leflunomide for patients with IgA nephropathy and whether the combination therapy surpass telmisartan in decreasing proteinuria and protecting renal function.

Methods: We enrolled 400 patients aged 18-55 years from 13 centers in Beijing who had proteinuria >0.3-3.5 g/day, baseline serum creatinine (Scr) ≤265 umol/L (3mg/dl).

Results: Comparison of 24-hr urinary protein excretion, the serum creatinine, eGFR, albumin, cholesterol and uric acid, before and after the therapy were assessed.

Conclusions: No statistically significant differences were observed for any baseline clinical data including age, gender, BMI, blood pressure, proteinuria, serum creatinine, eGFR, serum uric acid in the four groups (P>0.05). After treatment for 24 weeks, a significant decline of proteinuria was observed in the four groups (P<0.05), while those in group C (1.02±0.76 vs 0.77±0.42 g/24h) and group D (1.16±0.63 vs 0.87±0.49 g/24h) were decreased more significantly than in group A (1.15±0.87 vs 0.92±0.58 g/24h) and group B (1.11±0.83 vs 0.89±0.42 g/24h) (P<0.05). Mixed effects were showed that telmisartan, leflunomide, and telmisartan combined with leflunomide were effective in lowering proteinuria (P<0.01) by model analysis. The extent of serum creatinine decline in group C and group D displayed more significantly than that in group A and group B (P<0.05). The levels of eGFR in group C and group D were increased more than those in group A and group B. The decline of serum uric acid in group C and group D displayed more significantly than group A and group B (P<0.05). There were no significant differences in the results of albumin and cholesterol among the four groups (P>0.05). No obvious adverse reactions were found in the four groups.

Conclusions: In the selected patients with IgA nephropathy, telmisartan combined with leflunomide was safe and effective in decreasing proteinuria and protecting short-term renal function. Larger randomized studies would be needed to confirm these results in the long run.

SP308

A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY OF CORTICOSTEROID COMBINED WITH CYCLOPHOSPHAMIDE OR FK506 IN PRIMARY IgA NEPHROPATHY WITH MILD OR MODERATE RENAL INJURY

Pingyuan Shen1, Ya Li1, Xiaohui Wang1, Weiming Wang1, Hong Ren1, Wen Zhang1 and Nan Chen1

1Department of Nephrology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

Introduction and Aims: The aim of this study was to evaluate the efficacy and drug safety of cyclophosphamide or FK506 with corticosteroid in primary IgA nephropathy (IgAN) with mild or moderate renal injury.

Methods: From 2010 to 2011, 36 primary IgAN patients with 30ml/min<Scr<90ml/min and urinary protein excretion >1.02g/24h (with or without hypertension) were enrolled to this study prospectively. There were three groups (Corticosteroid, Corticosteroid combined with cyclophosphamide (CTX) or FK506), each group included 12 patients for 24-weeks treatment. In each group, corticosteroid initial dosage was 0.5-0.8mg/kg/d, decreasing the dosage gradually after 8 weeks.

Corticosteroid combined with CTX group: CTX 0.5-0.75g/m²/month; Corticosteroid combined with FK506 group: FK506 0.1mg/kg/d (effective serum drug concentration 6’10ng/ml), Maintenance period were 24 weeks: corticosteroid 10-15mg/d, CTX 0.5-0.75g/m²/week; FK506 0.05mg/d. Evaluation of the effect: (1) Remarkable effect: 24-hour urinary protein excretion <0.3g/24h, serum creatinine decreased >10% than baseline; (2) Effect: 24-hour urinary protein excretion decreased over 50% than pre-treatment and serum creatinine was stable; (3) Non-effect: 24-hour urinary protein excretion did not meet the above criteria, or serum creatinine increased >8% per year.

Results: 36 patients were enrolled, M 26F 10, average age 37.5±3.15years (20-70).

There is no difference among the three groups in their laboratory features at the baseline. After 3 months, 6 months and 12 months, 24-hour urinary protein excretion was decreasing 0.90±0.75, 0.76±0.73 and 0.35±0.35 in corticosteroid group; 1.40±1.24, 0.87±0.33, 1.43±0.59 in corticosteroid in combination with CTX group and 1.10±1.33, 0.78±0.69, 0.69±0.82 in corticosteroid combined with FK506 group respectively (P<0.05). By 6 months, the serum creatinine decreased both in corticosteroid group (Scr 111.72±32.3±umol/L) and corticosteroid combined with CTX group (Scr 111.33±7.76 umol/L) (P<0.05); while no change in corticosteroid combined with FK506 group. Remarkable effect: corticosteroid group 9 patients(75%), corticosteroid combined with CTX group and corticosteroid combined with FK506 group were both 7 patients(58%); Effect: corticosteroid group and corticosteroid combined with FK506 group both 3pts(25%); corticosteroid combined with CTX group 5 pts(42%); corticosteroid combined with FK506, group respectively included 1 hyperglycemia and 1 liver dysfunction in corticosteroid group, including 2 hyperglycemia, 1 IGT and 1 liver dysfunction in corticosteroid combined with FK506 group.

Conclusions: It suggested that CTX and FK506 were beneficial for controlling proteinuria without significant serum creatinine increasing.

SP309

RELATIONSHIP BETWEEN THE BODY MASS INDEX AND THE PROGRESSION OF IgA NEPHROPATHY EVEN IN LEAN INDIVIDUALS

Mamiko Shimamoto1, Issa Ohsawa1, Hyori Suzuki1, Seiji Nagamachi1, Yoshio Shimizu1, Satoshi Horkoshi1 and Yasuyuki Tomino1

1Division of Nephrology, Department of Medicine Juntendo University Faculty of Medicine Tokyo Japan

Introduction and Aims: In chronic kidney disease, obesity is an important risk factor for disease progression. Likewise, in IgA nephropathy (IgAN), several studies reported that excessive body weight (body mass index (BMI): 25 kg/m² or greater) had an impact on the prognosis. The impact of BMI, however, remains unclear in smaller individuals like Japanese. The objective of the present study is to determine the impact of BMI, metabolic factors on the prognosis of IgAN patients in Japanese.

Methods: All IgAN patients were diagnosed in the Juntendo University Hospital between 1999 and 2009. Patients with diabetes mellitus or autoimmune disease, purpura nephritis were excluded. There were 95 male (49.2%) and 98 female (50.8%) patients, and median age was 32.8±11.0 years old (range 12-65). Patients were divided into three groups equally according to BMI: Group L (lean group) (n=65, BMI: 15.57-20.18kg/m²), Group M (middle group) (n=64, BMI: 20.20-23.04 kg/m²) and Group O (obese group) (n=64, BMI: 23.11-31.89 kg/m²).

Results: No statistically significant differences were observed for any baseline clinical data including age, gender, BMI, blood pressure, proteinuria, serum creatinine, eGFR, triglyceride, LDL cholesterol, Uric acid, Hemoglobin, C-reactive protein, and albumin at the time of renal biopsy were analyzed. Levels of serum creatinine (sCr), protein was significantly delayed in Group O.

Conclusions: It is concluded that IgAN to reduce weight and treat their metabolic factors.
Introduction and Aims: Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. The basic defect lies within the IgA immune system and in peripheral blood leukocytes rather than local kidney abnormalities. Our previous work evidenced a more profound altered gene expression pattern in monocytes compared to B and T cells isolated from IgAN patients and thus our aim here was to study the monocyte subset more closely at a genome wide level. Human monocytes can be classified into two main subsets with distinctive characteristics: classical (CD14+CD16-) and non classical (CD14+CD16+) monocytes, the latter cells characterized by a more marked apoptotic propensity.

Methods: A total of 33 IgAN patients and 33 healthy subjects (HBD) were included in this study. Illumina microarray technology was used to evaluate global differences in gene expression between monocytes isolated from IgAN patients and HBD. Bioinformatic analysis was performed with GenomeStudio and Genespring software. The connectivity between genes was evaluated using Ingenuity Pathway Analysis. Aberrantly expressed genes and pathways were then validated in an independent set of patients with RT-PCR western blot and flow cytometric analysis.

Results: Bioinformatic analysis revealed 710 differently regulated probes with FDR-corrected p value 0.05 in IgAN patients. These probes were primarily involved in Apoptosis Signaling, mitochondrial dysfunction, tnfr2/1 and death receptor signaling canonical pathways. Four representative genes belonging to these pathways (TNF, CD83, TNRFSF1A, NDUFS3) were chosen for validation purposes and the normalized gene expressions obtained were in line with the gene expression array. All mitochondrial respiratory chain subunits were found modulated. In particular, the protein levels of NDUFS3 were statistically up-regulated in IgAN patients confirming an aberrant mitochondrial homeostasis. The enhanced apoptotic phenotype seen with the gene expression in monocytes was confirmed at the protein level, in fact CD14+ cells exhibited a significantly higher percentage of annexin-V and 7-AAD double positive staining. Next we demonstrated this phenotype was due to a different distribution of monocyte subsets in IgAN patients compared to HBD. Surprisingly we found that CD14+ CD16 subset was significantly expanded in all IgAN patients tested even though the total monocyte count was unchanged.

Conclusions: Taken together, our findings demonstrate an aberrant modulation of the mitochondrial respiratory system in monocytes isolated from IgAN patients and a specific up-regulation of NDUFS3. Furthermore, the aberrant expansion of the CD14+ CD16 subset in IgAN patients could explain the enhanced apoptotic function seen in these cells thus, revealing a potential pathogenetic role of these cells in IgAN.

SP310
ALTERED MONOCYTE GENE EXPRESSION AND EXPANSION OF CD14+CD16+ CELL SUBSET IN IG A NEPHROPATHY PATIENTS
Sharon N. Cox1, Grazia Serino1, Fabio Sallustio1,2,3, Francesco Pesce1,4 and Francesco P. Schena1,2
1Emergency and Organ Transplantation University of Bari Bari Italy, 2C.A.R.S.O. Consortium Valenzano, Bari Italy, 3P.1.T.Ea.Da Università del Salento Lecce Italy, 4Genomics of Common Disease, School of Public Health Imperial College London United Kingdom

SP311
RELIABILITY OF STATISTICAL MODELS TO PREDICT AN IGA NEPHROPATHY
Emile Kalbaccher1, Michel Ducher1, Denis Fouque1, Brigitte MacGregor1, Francois Combarnous2 and Jean Pierre Faurel1
1Nephrology hospital E Herriot Lyon France, 2Nephrology Clinique du Tonkin Lyon France

Introduction and Aims: Models are increasingly used in clinical practice to improve the accuracy of diagnosis. The aim of our work was to compare Bayesian network to logistic regression to forecast an IgA nephropathy (IgAN) from simple clinical and biological criteria.

Methods: Retrospectively, we pooled the results of all biopsies (n=155) performed by nephrologists in a specialist clinical facility between 2002 and 2009. Two groups were constituted at random. The first sub-group was used to determine the parameters of the models adjusted to data by logistic regression or Bayesian network, and the second was used to compare the performances of the models using Receiver Operating Characteristics (ROC) curves.

Results: An IgAN was found in 45 patients. Areas under the ROC curves provided by both methods were highly significant but not different from each other. Based on the highest Youden indices, sensitivity reached (100% vs 67%) and specificity (73% vs 95%) using the bayesian network or the logistic regression respectively.

Conclusions: A Bayesian network is at least as efficient as a logistic regression to estimate the probability of a patient suffering IgAN, using simple clinical and biological data obtained at consultation.

SP312
CORTICOSTEROID THERAPY IS THE MOST IMPORTANT FACTOR INFLUENCING TA PROTEINURIA AND RENAL SURVIVAL IN IGA NEPHROPATHY (IgAN)
C. Saricina1, F. Ferrario1, V. Terraneo1, A. Pan1, G. Fogazzi2, G. B. Visciano1, L. De Simone1, F. Rastelli1 and C. Pozzi1
1Nephrology and Dialysis Unit Bassini Hospital Cuneo Italy, 2Brotzu Hospital Cagliari Italy, 3Maggiore Hospital Milan Italy

Introduction and Aims: Time Average Proteinuria (TAP) is an important prognostic factor in patients (pts) with IgAN: when proteinuria remains <1 g/d, progression towards ESRD is rare. The aim of this study is to search for association between proteinuria <1 g/d (favourable prognostic factor) and some clinical variables, especially the treatment.

Methods: From 1989 to 2005, we enrolled 325 pts affected by IgAN, presenting any plasma creatinine values and proteinuria above 1 g/d. Mean follow-up was 65.3±31 months and pts were evaluated six months after the enrollment and then every year. The considered variables were: age, sex, histological score, blood pressure (BP), immunological therapy, RAS blockers and statins. Pts were divided in 3 groups according to mean proteinuria values at follow-up: group 1, pts with proteinuria steadily >1 g/d; group 2, pts with proteinuria in turn > or <1 g/d; group 3, pts with proteinuria steadily <1 g/d. Considered endpoints were ESRD, 100% and 50% increase of plasma creatinine.

Results: Pts were distributed as follows: 51 (15.7%) in group 1, 156 (48.0%) in group 2, 118 (36.3%) in group 3. At last observation, the percentage of pts who reached the endpoints of ESRD, 100% and 50% increase of plasma creatinine in group 1 was 46.5%, 48.7% and 64.1%, respectively, in group 2 10.6%, 17.5% and 30.0%, respectively, and in group 3 3.1%, 5.5% and 11.1%, respectively. In group 3 a stable reduction of proteinuria occurred in 66.9% by 6 months and in further 18.7% by 12 months. Therefore, proteinuria reduction occurred especially when pts received immunological treatment (first six months). Considering the immunological therapy, 43 pts had no treatment, 171 received steroids (ST) and 111 steroids+azathioprine (ST+A); in group 1, 41.0% of patients had no treatment, whereas 17.9% received ST and 41.1% ST+A; in group 2, 9.4% had no treatment, 58.1% received ST and 32.5% ST+A; in group 3, 9.5% had no treatment, 56.3% received ST and 34.1% ST+A. At logistic univariate analysis pts treated with ST or ST+A, compared to not treated pts, had more possibilities of reducing proteinuria <1 g/d (RRR 7.0 and 3.2 respectively; p <0.01). Age, sex, histological score, BP at baseline and use of statins were not associated with proteinuria steadily below 1 g/d; the use of RAS blockers resulted significant only in group 2 (p 0.03).

Conclusions: Our data show that the only factor associated with proteinuria steadily below 1 g/d was the immunological treatment. Particularly, ST resulted effective in reducing TAP whereas the add of A didn’t produce further advantages. Histological grade and hypertension at baseline didn’t seem to be associated with a low TAP. Use of RAS blockers had a significant role in pts with more variability of proteinuria values.

SP313
HIGH SERUM AND URINE NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) LEVEL IS AN INDEPENDENT PREDICTOR OF RENAL PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY
Imh Soo Kwak1, Eun Young Seong2, Harin Rhine1, Dong Won Lee2, Soo Bong Lee3, Byung Yoon Yang1, Min Ji Shin1 and Il Young Kim2
1Nephrology Pusan National University Hospital Busan Republic of Korea, 2Yangsan- Pusan National University Hospital Yangsan Republic of Korea

Introduction and Aims: Tubulo-interstitial injury plays an important role in the progression of Immunoglobulin A (IgA) nephropathy and the neutrophil
gelatinase-associated lipocalin (NGAL) is one of the most sensitive tubule markers. The aim of our study is to investigate if the serum or urine NGAL might predict the prognosis in patients with IgA nephropathy.

**Methods:** From January 2005 to December 2010, patients with biopsy proven IgA nephropathy whose serum and urine samples at the time of kidney biopsy were conserved in a frozen state, were enrolled in this study. We retrospectively reviewed their clinical data and followed them up till October 2012. Serum and urine NGAL levels were measured using ELISA kit. Renal progression was defined as eGFR decline more than 50% or progression to end-stage renal disease (ESRD).

**Results:** A total of 121 patients were enrolled in this study. During the median follow up period of 41.49 months, renal progression was found in 9 patients (7.4%). In our study, serum or urine NGAL alone could not predict renal progression, however, when the serum and urine NGAL levels were combined, the high NGAL group independently predicted the renal progression (HR=4.58, 95% CI=1.13–18.59, p=0.03) along with the tubular damage graded by the Oxford classification T2 (HR=6.61, 95% CI=1.31–28.91, p=0.004). The Kaplan-Meier curve for renal survival showed a significantly higher renal progression in the high NGAL group (Log rank, p=0.004).

**Conclusions:** In patients with IgA nephropathy, high serum and urine NGAL levels at the time of kidney biopsy, predicted renal progression.

**SP313**

**UP-REGULATION OF URINARY MARKERS PREDICTS OUTCOME OF IgA NEPHROPATHY BUT THEIR PREDICTIVE VALUE IS INFLUENCED BY TREATMENT WITH IMMUNOSUPPRESSION**

Maria J. Stangou, Christos Bantis, Stratis Kasimatis, Maria Skoularopoulou, George Toulikeris, Afroditi Pantzaki, Alkaterini Papagianni and George Efstathiadis

**1Department of Nephrology Hippokration Hospital Thessaloniki Greece, 2Department of Pathology Hippokration Hospital Thessaloniki Greece**

**Introduction and Aims:** Steroids and immunosuppressants can delay progression of renal function in IgAN, but their possible effect in local cytokines has not been studied.

**Methods:** Histology in 53 IgAN patients (MF 35/18 age 40.5yrs (17-65)) was evaluated by Oxford classification system. IL-1β, -2, -4, -6, -10, -12 and -17, INF-γ and MCP-1 were measured subsequently by multiplex cytokine assay in first morning urine samples taken at the day of renal biopsy. After a 6 month course with RASInhibitors+fish oils, 35/53 patients, group A, responded and continued on the same treatment, while in 18/53 who did not respond, group B, steroids+azathioprine were added.

**Results:** The presence of endocapillary proliferation had significant correlation with the urinary excretion of pro-inflammatory and pro-fibrotic cytokines (IL-1β, MCP-1, IL-17, INF-γ, IL-6 and IL-10). Serum creatinine at time of diagnosis had significant correlation with proteinuria (p=0.02), urinary levels of IL-1β (p=0.03), IL-2 (p=0.01) and MCP-1 (p=0.03). GFR was reduced from 65.29 to 57.34ml/min, p=0.005 in group A and stayed stable in group B patients (GFR from 63±24 to 61±30ml/min, p=NS). Most of the measured cytokines in the urine predicted deterioration of renal function in group A, but the urinary excretion of IL-1β, and IL-6 seemed to predict renal function outcome in both groups of patients.

**Conclusions:** Several cytokines are excreted in the urine of patients with IgAN, and their levels predict outcome of the disease. Steroids+aza may exert their beneficial effect through production or activation of most cytokines.

**SP315**

**EFFECT OF LEUKEMIA INHIBITORY FACTOR (LIF) ON IgA1-PRODUCING CELLS FROM TONSILS OF PATIENTS WITH IgA NEPHROPATHY (IgAN)**


1University of Alabama at Birmingham Birmingham AL United States, 2Juntendo University Tokyo Japan, 3Palacky University Olomouc Czech Republic, 4Columbia University New York NY United States

**Introduction and Aims:** IgA1-producing cells from tonsils of patients with IgAN secrete galactose-deficient IgA1 (Gd-IgA1), a key factor in the IgAN pathogenesis. Upper-respiratory tract infections frequently associate with episodes of macroscopic hematuria in IgAN patients, but little is known about the role of tonsils and production and glycosylation of IgA1 by tonsillar cells. Moreover, genetic studies revealed an association of a locus encompassing the gene encoding LIF with serum IgA levels in patients with IgAN. LIF, a member of IL-6 family of cytokines, is involved in mucosal immunity. Here, we assessed the effect of LIF on IgA1 production and glycosylation using IgA1-secreting cells derived from tonsils of IgAN patients and controls.

**Methods:** We assessed the effect of LIF, as compared to IgL as a control, on production and O-glycosylation of IgA1 in EBV-immortalized IgA1-secreting cells derived from tonsils of IgAN patients (IgAN-T) and controls (patients with sleep apnea syndrome; HC-T). IgA1-secreting cells derived from the circulation of IgAN patients (IgAN-P) and healthy controls (HC-P) served as controls. Gd-IgA1 was determined by lectin ELISA with Helix aspersa agglutinin (HAA).

**Results:** LIF decreased production of IgA1 in IgAN-T and HC-T (22.4%±14.4% and -3.7%±2.2%, as well as in IgAN-P and HC-P (9.1%±6.1% and -6.7%±4.1%). Conversely, IL-6 increased production of IgA1 in IgAN-P and HC-P by 55.8% and 16.9%, respectively, whereas the increases in IgA1 production in IgAN-T and HC-T were less robust (14.5% and 3.5%). Cells from IgAN patients (IgAN-T and IgAN-P) secreted more Gd-IgA1 compared to the cells from controls (HC-T and HC-P) (28.0% and 24.2%, 13.5% and 15.5%; expressed as HAA reactivity; 100% is binding to standard Gd-IgA1). LIF increased Gd-IgA1 production by IgAN-T but not by HC-T (relative change, 24.2%±3.7% vs. -0.1%±0.1%). LIF increased production of Gd-IgA1 in IgAN-P but not in HC-P (relative change, 15.3%±3.6% vs. -1.5%±2.8%; p<0.01). IL-6 increased production of Gd-IgA1 in IgAN-T but not in HC-T (relative change, 32.5%±3.7% vs. -0.1%±0.1%) and increased Gd-IgA1 production in IgAN-P but not in HC-P (relative change, 24.0%±15.9% vs. -4.0%±4.2%; p<0.01). Thus, LIF or IL-6 stimulation of IgA1-secreting cells from IgAN patients increased production of Gd-IgA1.

**Conclusions:** IgA1-secreting cells from IgAN patients responded abnormally to a cytokine encoded in a locus identified by genetic association studies. Understanding the abnormalities will aid development of new diagnostic approaches and future IgAN-specific therapy.
e-GFR was calculated using the MDRD formula in adults and Schwartz formula in children. The slope of e-GFR was calculated from serial measurements over the follow-up.

**Introduction and Aims:**

In a retrospective study of a large cohort of European subjects with IgAN, there are three baseline variables associated with ESRD: sex [HR = 0.17 (0.04-0.03)], systolic blood pressure [HR = 1.05, 95% CI 1.02-1.08], and total renal survival time. By multivariate Cox proportional hazards model, four variables were independently related to ESRD which included serum albumin [HR = 0.53 (0.32-0.88), p = 0.02], systolic blood pressure [HR = 1.02 (1.00-1.04), p = 0.04], eGFR [HR = 0.96 (0.94-0.97), p = 0.00], and hemoglobin [HR = 0.83 (0.72-0.94), p = 0.01]. In Cre+ group, there are three baseline variables associated with ESRD: sex (HR = 0.17 (0.04-0.85), p < 0.03), systolic blood pressure (HR = 1.10, 95% CI 1.02-1.09, p = 0.01), and eGFR (HR = 0.94 (0.91-0.97), p < 0.001).

**Results:**

There are 226 patients in Cre+ group and 313 patients in Cre- group. The mean follow-up time is 3 years. Mean age was 37 ± 12.2 in Cre+ group and 35.0 ± 12.1 years in Cre- group. Of all patients in Cre+ group, 91 (40.3%), 94 (41.6%), 30 (13.3%), and 11 (4.9%) had the percentage of crescents was <10%, 10-25%, 25-50%, >50%, respectively. At renal biopsy, patients in Cre+ group had lower Hemoglobin (12.41 ± 2.13 vs 13.12 ± 2.12 g/dl, p = 0.001), higher proteinuria [1.76 ± 0.04 (11.26) vs 1.61 (0.03-13.91 g/dl), p < 0.001] than in Cre- group. On histology, Cre+ group had a higher percentage of mesangial hypercellularity (44.3 vs 37.1%, p = 0.015) and endocapillary hypercellularity (60.6% vs 17.0%, p < 0.001), higher intensity of C3 deposition (83.0% vs 73.4%, p = 0.016). In total, ESRD occurred in 56 individuals. Patients in Cre+ and Cre- group had a similar renal survival time. By multivariate Cox proportional hazards model, four variables were independently related to ESRD which included serum albumin [HR = 0.53 (0.32-0.88), p = 0.02], systolic blood pressure [HR = 1.02 (1.00-1.04), p = 0.04], eGFR [HR = 0.96 (0.94-0.97), p = 0.00], and hemoglobin [HR = 0.83 (0.72-0.94), p = 0.01]. In Cre+ group, there are three baseline variables associated with ESRD: sex (HR = 0.17 (0.04-0.85), p < 0.03), systolic blood pressure (HR = 1.10, 95% CI 1.02-1.09, p = 0.01), and eGFR (HR = 0.94 (0.91-0.97), p < 0.001).

**Conclusions:**

Our study suggested crescent is associated with clinical and pathological characteristics in patients with IgAN. While crescent is not associated with ESRD, IgAN patients with crescent have different risk factors for ESRD compared with those without crescent.

**SP319 EVALUATION OF CELIAC DISEASE IN CHILDREN WITH HENOCH SCHOLENLEIN PURPURA**

Alper Soylu1, Yesim Ozturk1, Yavuz Dogan1, Derya Ozmen2, Ozlem Yilmaz1 and Salih Kavukcu1

1Pediatrics Dokuz Eylul University Medical Faculty Izmir, Turkey, 2Microbiology Dokuz Eylul University Medical Faculty Izmir, Turkey

**Introduction and Aims:**

Prevalence of celiac disease (CD) in children is around 1 per cent in Europe and United States. The rate of seropositivity has been reported to be 2-5% in healthy Turkish children. The frequency of other autoimmune diseases is increased in CD. IgA associated skin and systemic disorders (IgA nephropathy) are found among these diseases. Henoch Schonlein purpura (HSP) is an IgA associated autoimmune disease. However, apart from two case reports, there is no study evaluating the association of HSP with CD. We aimed to evaluate the prevalence of latent CD in children with HSP.

**Methods:**

Children with HSP over 3 years of age were enrolled in the study. They were evaluated for demographic, anthropometric, clinical and laboratory data including urinalysis, complete blood count, serum albumin, creatinine, IgA levels. In addition, anti-tissue transglutaminase IgA (ELISA), anti-endomysium IgA (IFAT), anti-gliadin (GAF3X, deaminated) IgA (IFAT) and anti-gliadin (GAF3X, deaminated) IgG (ELISA) antibody levels were determined. Seropositive patients were evaluated by endoscopic small bowel biopsy. The rate of CD seropositivity in HSP patients was compared to the rate in healthy Turkish children by the test for the statistical significance of two percentages.

**Results:**

Celiac serology was evaluated in 42 children (25 male, mean age 11.2 ± 3.6 years) with HSP. There was no patient with growth failure or having symptoms higher (p <0.05) in pts with E1, S1 vs. E0, S0. IgA/C3 serum ratio was significantly higher (p <0.05) in children with M1, S1 and T1 vs. M0,S0,T0, in E1 vs E0 NS. Significantly higher values of IgA/C3 (p <0.05) were revealed in pts with 4 risk factors of poor histological progression in OC (M1+E1+T1+V=4) vs. pts without risk factors (M1+E1+T1+V=0).

**Conclusions:**

1. The serum IgA/C3 ratio may be a marker severe histological lesions in children with IgAN.

2. The renal biopsy Oxford Classification performed in children at the onset of the disease is useful in evaluation of IgAN severity.

---

**SP317 RISK OF PROGRESSION OF IgA NEPHROPATHY (IgAN) IN CHILDREN BASED ON OXFORD CLASSIFICATION (OC) AND IgA/C3 SERUM RATIO**

Małgorzata Mizerska-Wasiak1, Jadwiga Maldyk2, Agnieszka Rybi-Szuminska3, Agnieszka Finicz-Adamek1, Eliza Bienias2, Katarzyna Gadomska-Prokop1, Ryszard Grenda4, Malgorzata Maliszewska1, Roman Stankiewicz1, Anna Wasilewska1 and Maria Roszkowska-Blaim1

1Dept. of Pediatrics and Nephrology Medical University of Warsaw Warsaw Poland, 2Dept of Children Pathology Medical University of Warsaw Warsaw Poland, 3Dept. of Pediatrics and Nephrology Medical University of Białystok Białystok Poland, 4Dept of Pediatrics and Nephrology Children's Hospital Torun Poland, 5Dept of Nephrology and Kidney Transplantation The Children's Memorial Health Institute Warsaw Poland

**Introduction and Aims:**

The aim of the study was to assess the risk of progression of IgAN in children at the onset of the disease, based on OC and IgA/C3 serum ratio. Methods: A total of 58 children, in mean age 9.56 ± 4.99 yrs, with IgAN from 5 nephrology centers in Poland were enrolled. Renal biopsy was performed in 0.9, median 0.5 (0.08-4.75) yrs after the first symptoms of IgAN. The histological features were scored ac. to OC. (M-mesangial hypercellularity, E-endocapillary hypercellularity, S-segmental sclerosis, T-tubular atrophy/interstitial fibrosis; absent = 0, present = 1). Proteinuria, IgA/C3 serum ratio were analyzed depending on MEST and histological number of risk factors.

**Results:**

Results of proteinuria and IgA/C3 ratio in MEST groups are presented tabl. 1. Most commonly histological lesions were: M1-77.6% pts, S1-37.9% Proteinuria was
PLASMA NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A NEW INDEPENDENT PREDICTOR OF PROGNOSIS IN PATIENTS WITH IGA NEPHROPATHY

Ji-Youn Choi1,2, Ga-young Park1,2, Hee Yeon Jung1,2, Kyung Hoon Kim1,2, Owen Kwon1,2, Jang-Hee Choi1,2, Chan-Duck Kim1,2, Yong-Lim Kim1,2* and Sun-Hee Park1,2

1Division of Nephrology, Department of Internal Medicine Kyungpook National University School of Medicine Daegu Republic of Korea, 2Clinical Research Center for End Stage Renal Disease in Korea Daegu Republic of Korea

Introduction and Aims: The clinical course of IgA nephropathy (IgAN) is variable as a known specific biomarker of acute kidney injury (ARI). We aimed to evaluate the value of plasma NGAL as an independent predictor associated with disease prognosis in IgAN.

Methods: A total of 93 patients with biopsy-proven IgAN in a single center were evaluated. Plasma NGAL was measured by commercial ELISA kit (R&D Systems, Minneapolis, MN). Adverse renal outcome was defined as CKD stage 3 or above at last follow-up. Pearson’s correlation coefficient and Cox regression were used for analysis.

Results: There were 50 men and 43 women with a mean age of 35 years (18.77 years). Plasma NGAL ranged between 21.67 and 446.40 ng/ml (median 125.13 ng/ml) and it was correlated with age (r=0.326, p=0.001), creatinine (r=0.403, p<0.001), eGFR (r= -0.432, p<0.001), uric acid (r=0.309, p=0.003) and protein/creatinine ratio (PCR) (r=0.388, p=0.003). Plasma NGAL was also significantly associated with tubular injury in pathology (p=0.026). During mean follow-up of 37.6 months, the patients with CKD stage 3 or above were 13 (14%). In a multivariate Cox regression model, hypertension (HR=7.289, CI 1.448-36.682, p=0.016), proteinuria >1g/day (HR=4.724, CI 1.227-18.182, p=0.024) and plasma NGAL (HR=1.010, CI 1.002-1.018, p=0.018) were independent predictors associated with the outcome of CKD stage 3 or above.

Conclusions: Plasma NGAL was well correlated with other clinical parameters previously known as predictors of disease prognosis of IgAN and it was independent predictor of adverse renal outcome. We suggest plasma NGAL as a new independent predictor of prognosis in IgAN, while further studies are needed to confirm the usefulness of plasma NGAL as a predictor.
and the cANCA positive patients. We found a significant inverse correlation between the sLox-1 and BVAs values (n = 22; r² = 0.43; p < 0.001).

Conclusions: Our present finding of a decreased concentration of circulating soluble Lox-1 in ANCA vasculitic patients, with regard to previous observations of the overexpression of Lox-1 gene in the organ tissue, raises the possibility that Lox-1 may be highly expressed locally in response to proinflammatory stimuli, and via a feed-back effect decreases the circulating soluble receptor level. It could be suggested that serum soluble Lox-1 concentration might be a useful marker for the disease activity in ANCA-associated renal vasculitis. Further investigations are needed to clarify the pathomechanism of the decreasing receptor concentration in active ANCA vasculitis.

**SP324 INCIDENCE AND OUTCOMES OF RENAL ANCA-ASSOCIATED VASCULITIS IN SOUTHWEST IRELAND 2007-2012**

Philip H. Breedin1, Mark Canney2, Claire Kennedy2, Liam D. Plant2 and Michael R. Clarkson2

1School of Medicine University College Cork Cork Ireland, 2Department of Renal Medicine Cork University Hospital Cork Ireland

Introduction and Aims: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease with a one-year mortality of approximately 90% in untreated patients. Renal involvement is a common manifestation, and may lead to end-stage kidney disease (ESKD). Treatment requires systemic immunosuppression and carries inherent risks, including sepsis. Our unit is the sole tertiary referral centre for renal AAV in Southwestern Ireland. We identified all patients diagnosed with Renal AAV from 2007 - 2012. Our objectives were to calculate the incidence of Renal AAV in Ireland and to describe the clinical features and outcomes of Renal AAV in this patient population.

Results: We identified a cohort of patients with a first diagnosis of AAV with clinical evidence of renal involvement, over a six year period using our integrated laboratory and patient database. A retrospective review of patient charts, correspondence and laboratory results was performed.

Conclusions: 59 patients met the inclusion criteria. Of these, 34 (58%) were male. The median age at diagnosis was 62 years (IQR 55-72); 42% had clinical, radiological or histological evidence of pulmonary involvement; 36% had upper airway involvement. 64% were MPO positive and 36% were PR-3 positive. The incidence of AAV with renal involvement in Southwestern Ireland over the six year period was 15.6 cases per million person years (95% CI 11.9-18.9). Median creatinine at presentation was 285μmol/L (IQR 147-549), with 32% (12 out of 38) of patients admitted with sepsis in the follow-up period. 32% (12 out of 38) of patients treated with oral cyclophosphamide (CYC) were admitted with sepsis during the follow-up period as compared to 15% (2 out of 13) of patients treated with IV CYC. 17 (35%) patients received plasma exchange (PEX). The median creatinine of PEX-treated patients at presentation compared to non-PEX treated patients was 428μmol/L (IQR 147-492) vs 276μmol/L (IQR 165-344), with 71% of patients receiving PEX having significant pulmonary involvement. At one year the PEX treated patients had a median creatinine of 170μmol/L (IQR 112-219) vs 134μmol/L (IQR 112-168) in the non-PEX treated group reflecting the more severe initial presentation in the former group. The patient survival rate at one year was 92% (n=48) comparing favourably to international published outcomes. 10 patients (17%) developed ESKD during the follow-up period. Two of these patients were subsequently transplanted without complication. Only one patient dialysis-dependent at 6 months developed ESKD thereafter. The patient survival at one year was 92% (n=48) comparing favourably to international published outcomes. 10 patients (17%) developed ESKD during the follow-up period. Two of these patients were subsequently transplanted without complication. Only one patient dialysis-dependent at 6 months developed ESKD thereafter.

Conclusions: These data suggest that the incidence and one year mortality rates of renal AAV in Ireland fall within international norms. Furthermore, they support the observation from randomized clinical trials that pulse IV cyclophosphamide is associated with fewer infectious adverse events as compared to daily oral therapy.

**SP325 RITUXIMAB MONOTHERAPY (WITHOUT CYCLOPHOSPHAMIDE) IN ANCA ASSOCIATED VASCULITIS IN PATIENTS WITH SERUM CREATININE ABOVE AND BELOW 500 μmol/L**

Noshabia Naz1, Mithyrjyaj Hirrmath1, Anindita Banerjee1 and Yaser Shah1

1Renal Wirral University Teaching Hospital Wirral Mersyside United Kingdom

Introduction and Aims: There is limited data on using rituximab (without cyclophosphamide combination) as the primary immunosuppressive agent in ANCA associated vasculitis with serum creatinine > 354 μmol/L. RAVE excluded such patients; in RITUXIVAS patients received at least 2 doses of intravenous cyclophosphamide along with rituximab. We used rituximab as the main immunosuppressive agent (without cyclophosphamide combination) as induction therapy in 32 ANCA associated vasculitis patients including 15 patients with serum creatinine > 354μmol/L. We grouped our patients into a presenting creatinine of higher or less than 500μmol/L. Our aim was to investigate the renal outcome in these two groups in the first year of presentation and to identify rates of infection, relapse, malignancy and mortality between these groups.

Methods: We retrospectively assessed new ANCA associated vasculitis with acute renal failure. Patients were grouped into two based on their presenting serum creatinine. Group A with serum creatinine < 500μmol/L and Group B with serum creatinine >500μmol/L. Serum creatinine at 3, 6 and 12 months of presentation was compared with baseline serum creatinine. Incidence of infection, mortality, malignancy and relapse rate was also compared in these 2 groups at their first 12 months of treatment.

Results: All patients received IV methyl prednisolone followed by oral prednisolone with rituximab 375 mg iv weekly for 4 weeks. 11 (7 with serum creatinine >500 μmol/L) also received plasma exchange. Table 1 show a significant improvement in serum creatinine in both groups at 3, 6 and 12 months of presentation. Serum creatinine plateaued at 3 months in Group A but took more than 3 months in Group B suggesting severe ischemia and acute tubular necrosis in group. We also found no statistically significant difference in infection, relapse, malignancy and mortality rate in the 2 groups at their first year of rituximab therapy.

Conclusions: We concluded that rituximab was a very effective and well tolerated induction agent without cyclophosphamide combination in ANCA associated vasculitis irrespective of the level of renal failure.

**SP326 CARDIOVASCULAR OUTCOMES AND PROGNOSTIC PREDICTORS IN ANCA-ASSOCIATED VASCULITIS**

Claudia Yuste1, Alina Casian2, Cristina Jironda3 and David Jayne2

1Nephrology Gregorio Marañón Hospital Madrid Spain, 2Vasculitis and Lupus Clinic Asturias Hospital Cambridge Cambridgeshire United Kingdom, 3Nephrology Carlos Haya Hospital Malaga Andalucia Spain

Introduction and Aims: ANCA associated vasculitis (AVV) (granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)) is associated with an increased frequency of cardiovascular events (CVE). Objectives: To characterize cardiovascular outcomes and predictors, including the role of vasculitis therapies, for CVE/death in AAV.

Methods: A single center retrospective review of 307 AAV patients (173 GPA, 134 MPA, 47% male, 12% diabetic; mean age 53 [±17] years with follow-up 6.1 [±3.5] years. The primary end-point was CVE (defined as acute coronary syndrome, new onset angina, symptomatic peripheral vascular disease, stroke or transient ischaemic attack), or death. Results: Fifty-one CVE occurred in 42 patients (13.6%) with 28 (9%) deaths. 15.7% CVE occurred at the onset of AAV, 57.4% CVE/death occurred within first year of AAV diagnosis, and 27.8% between 1 - 5 years. Independent predictors for the end-point (CVE/ death) were: maintenance prednisolone dose (hazard ratio (HR) 169.6 (95% CI 1.18-2400), cumulative cyclophosphamide dose (HR 15.98 [0.005-0.83]), haemoglobin level at the end of follow-up (HR 0.6 [0.262-0.987]), serum PR3-ANCA levels at onset (HR 0.97 [0.995 – 0.99]) and history of prior CVE (HR 5.3 [1.05-27.69]). A cumulative RTX dose <6g was associated with higher maintenance prednisolone dose (p=0.016).

Conclusions: CVE/death risk in AAV patients is especially high within the first 1 and 5 years of diagnosis. Prior CVE, low serum PR3-ANCA levels at onset and lower haemoglobin at the end of follow-up are associated with increased risk. Intensive immunosuppressive treatment of AAV at onset and avoidance of high long-term prednisolone dosage may have a protective effect against atheroclerosis. Rituximab therapy was associated with a steroid-sparing effect.

**SP327 RITAZAREM: AN INTERNATIONAL, OPEN LABEL, RANDOMISED CONTROLLED TRIAL COMPARING RITUXIMAB WITH AZATHIOPRINE AS MAINTENANCE THERAPY IN RELAPSING ANCA ASSOCIATED VASCULITIS**

Rona Smith1, Michelle Liew1, Rachel Jones1, Peter Merkel2 and David Jayne1

1Medicine Addenbrookes Hospital Cambridge United Kingdom, 2Rheumatology University of Pennsylvania Philadelphia PA United States

Introduction and Aims: Prior to the availability of effective therapy, ANCA associated vasculitis (AAV; granulomatosis with polyangiitis (GPA), Wegener’s), microscopic polyangiitis (MPA) had a mortality of 93% within two years, primarily due to renal

---

**Downloaded from https://academic.oup.com/ndt/article-abstract/28/suppl_1/i175/1838478 by guest on 24 January 2019**
and respiratory failure. The introduction of glucocorticoids and cyclophosphamide has transformed survival, with five year survival rates nearing 80%. AAV has become a chronic relapsing disorder, with progressive organ damage and disability affecting over 95% of patients. Cumulative exposure to glucocorticoid and immunosuppressive drugs contributes to toxicity and organ damage. 50% of patients relapse within five years and 10-20% have a refractory disease course. Novel therapeutic strategies are required for these patients.

Methods: RITAZAREM (EudraCT 2012-001102-14; ClinicalTrials.gov NCT01697267) is a 1:1 parallel, open randomized trial evaluating the efficacy of rituximab or azathioprine maintenance therapy in relapsing AAV. 190 patients with relapsing AAV will be enrolled across Europe, North America, and Australasia to receive rituximab (4 x 250mg/m^2), and glucocorticoid, induction therapy. Those with stable disease at month 4 will be randomised to receive repeat rituximab (1g at 4, 8, 12, 16, 20 months) or azathioprine (2mg/kg/day, stopping at month 27) maintenance therapy. All patients will receive glucocorticoids (standardized taper) concomitant with their allotted maintenance regimen. The primary objective is to demonstrate whether or not fixed interval, repeat rituximab is superior to azathioprine in the prevention of disease flares in AAV patients with relapsing disease. Secondary objectives are to demonstrate sustained disease remission beyond the 24 month treatment period, long term safety of rituximab administration, and the optimal remission maintenance therapy in AAV following induction of remission with rituximab. The primary endpoint is the time to disease relapse from randomisation. Patients will be followed, after the 24 month treatment period, for 12 months (minimum) and 24 months (maximum). There will be a 1-month follow up at the trial when the last patient reaches 12 months follow-up, 36 months after entry.

Results: RITAZAREM is a joint venture of two international collaborative networks, the European Vasculitis Study Group (EVUS) and the Vasculitis Clinical Research Consortium (VCRC). Rituximab is supplied free of charge by Roche and Genentech. RITAZAREM will inform the future standard of care for patients with AAV, and provide data describing the long term safety of rituximab maintenance in AAV patients.


### SP329 ANTI-PHOSPHOLIPID NEPHROPATHY ONLY BELONGS TO MYAKIS I IIA CLASSES, ALWAYS IN ASSOCIATION WITH LUPUS ANTICOAGULANT, BUT NEVER ANTI-B2GPI ANTIBODIES

Cristina Izzo^1^, Marco Quaglia^1^, Elisabetta Radin^1^, Andrea Airola^1^, Roberta Fenoglio^1^, Elisa Lazzarich^1^ and Piero Stratta^1^  
^1^Clinical and Experimental Medicine, Nephrology and Transplantation Amedeo Avogadro University - Maggiore Hospital Novara Italy

Introduction and Aims: Updated Sapporo criteria have provided a tool which should allow clinicians to better classify patients (pts) with anti-phospholipid antibodies (aPL) and anti-phospholipid syndrome (APS).

Methods: In pts with biopsy-proven lupus nephritis (LN) and positivity for Lupus Anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein antibodies (anti-β2GPI) we analysed: APS, APS-associated nephropathy (APSN) and main clinical outcomes, employing as classifying criteria Myakis-Class I (any complementation), IIa (LA only), IIb (aCL only) and IIc (anti-β2GPI only).

Results: Out of 101 pts, 70 were aPL negative and 31 aPL positive: 18 Class I, 10 Class IIa, 1 Class IIb, 2 Class IIc. Overall LA was present in 27/31 (87%), triple association in 4/18 (22.2%) and anti-β2GPI in 8/31 (25.8%). APS was present in 15/31 aPL-positive pts: 7 Class I, 3 Class IIa and 1 Class IIb. APSN was present in 9 pts; 5 in Class I and 4 of Class IIa; all pts with APS were LA positive and anti-β2GPI negative. In 3 pts (2 pts of Class I and 1 of Class IIa) APSN was an isolated histological picture, whereas in 6 other pts (3 pts of Class I and 3 of Class IIa) typical lesions of LN coexisted (5 diffuse proliferative LN and 1 Membranous nephropathy). Multivariate analysis showed that aPL significantly worsen thrombotic-free survival but do not reduce renal survival, which is instead much worse in proliferative classes of LN (HR 5.37). These classes were significantly less represented in aPL positive pts than in negative ones (35% vs 60%, p = 0.03). Five pts who started dialysis had APSN (Q2=7.52, p=0.006).

Conclusions: These findings confirm that LA is a strong risk factor for APSN and suggests that anti-β2GPI antibodies positivity may have a protective role: aPL positivity alone does not worsen renal survival, probably because of a lower frequency of proliferative classes in this subset of pts, whereas coexistence of APSN is a risk factor for ESRD.

### SP329 THE DELETEROUS IMPACT OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ON THE OUTCOME OF LUPUS NEPHRITIS: A CASE-CONTROL STUDY

Vivian L. Ounisic^1^, Maria J. Araujo^1^, Ligia C. Battaini^1^, Lectricia B. Jorge^1^, Cristiane B. Dias^1^, Myrthes Toledo-Barros^2^, Rui Toledo-Barros^1^ and Viktoria Worrow^1^  
^1^Nephrology University of São Paulo São Paulo Brazil, ^2^Clinical Immunology University of São Paulo São Paulo Brazil

Introduction and Aims: Few studies have analyzed the impact of anti-neutrophil cytoplasmatic antibody (ANCA) on the outcome of lupus nephritis (LN). The aim of this study was to evaluate the influence of ANCA seropositivity in the renal outcome of LN.

Methods: A retrospective analysis was carried out on all SLE patients (345) submitted to a kidney biopsy between 1999-12. Patients that fulfilled ACR lupus criteria and tested for ANCA were enrolled. Positive ANCA patients (POS) were randomly matched to ANCA seronegative patients (NEG) according to the type of LN and baseline clearance (MDRD simplified formula). Clinical and laboratory data were collected at baseline, after one year and at the end of follow up. Treatment was decided by the clinical staff based on conventional literature protocols.

Results: We included 128 patients (32 POS/96 NEG). Pertinuous ANCA was detected in 87.5% (n=28) of POS patients. At baseline, POS and NEG groups were similar regarding age, complement level, ANA, anti-DNA antibody; eGFR (46±36 vs44±29ml/min/1.73), proteinuria (3.4±1.6 vs 4.6±4.4 g/day), WHO LN classes, histological activity index, chronicity index, vascular lesions and follow up time. Interestingly, after one year of follow up, POS group was significantly associated with a lower serum C3 (86.7±22vs106±53;delta p=0.01) and positive Anti-dsDNA (66%vs33% p<0.01). At the end of follow up, the POS group showed a tendency to have a lower eGFR (56±37vs71±36ml/min/1.73 p=0.09) as well as more patients with eGFR<60ml/min(56,3% vs33,3% p=0.03). Finally, logistic regression analysis showed that ANCA is an independent predictor of eGFR<60ml/min during follow up, even after adjustments for initial eGFR and chronicity index.

Logistic Regression Analysis

<table>
<thead>
<tr>
<th>OR</th>
<th>95%IC</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.62</td>
<td>1.3-9.46</td>
<td>0.013</td>
</tr>
<tr>
<td>0.98</td>
<td>0.97-1.0</td>
<td>0.064</td>
</tr>
<tr>
<td>1.4</td>
<td>1.1-1.7</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Conclusions: In our study, positive ANCA was significantly associated with a worse renal outcome of LN when compared to matched negative ANCA patients.
Risk factors for maternal and fetal complications are: decreased renal function at conception and pre-existing chronic hypertension. Thrombophilia and nephropathy were not risk factors for maternal and fetal adverse events.

SP330

MYCOPHENOLATE AS MAINTENANCE THERAPY FOR LUPUS NEPHRITIS WITH IMPAIRED RENAL FUNCTION

Francisco Riverast1, Alfonso Segarrast2 and Manuel Pragast3 on behalf for the Glomerular Spanish Glomerular Study Group (GLOSEN)3
1Nephrology Hospital General de Ciudad Real Ciudad Real Spain, 2Nephrology Hospital Vall d’Hebron Barcelona Spain, 3Nephrology Hospital Universitario 12 de Octubre Madrid Spain

Introduction and Aims: Mycophenolate (MF) is effective as maintenance treatment after induction therapy in patients with lupus nephritis (LN). However, little is known about its role in patients with impaired renal function. The purpose of this study was to evaluate the efficacy and safety of MF as maintenance therapy for LN and its association with renal function.

Methods: Data were obtained for 56 patients from 13 Spanish renal units who were receiving MF as maintenance therapy for LN. All of them had received intravenous cyclophosphamide as induction therapy. Patients were classified into 2 groups according to renal function at the onset of MF treatment: Group 1 (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m²) and Group 2 (eGFR <60 mL/min/1.73 m²). Primary endpoints of the study were the rates of renal relapses and responses (partial or complete) and their relationship with baseline renal function. Secondary outcomes were the appearance of side effects during treatment.

Results: At initiation of MF treatment, there were no differences between groups except age, hemoglobin levels, anti-DNA antibody titer, proteinuria and renal function. In Group 1 (n=38) eGFR was 98±34 mL/min/1.73 m² and in Group 2 (n=18) was 43±14 mL/min/1.73 m². Exposure to prednisone and MF was similar. The number and percentage of cases that relapsed are indicated in Table 1.

Conclusion: Our study shows that pregnancy in patients with LN can be completed successfully, thanks to a multi-disciplinary approach in specialized centers, with the preconception assessment of the relative risk and through adequate prophylaxis of adverse events.

SP331

WHY HAVE OUTCOMES OF LUPUS NEPHRITIS BEEN IMPROVING OVER THE LAST 40 YEARS? A MONOCENTRIC EXPERIENCE

Marco Quaglia1, Elisabetta Radini2, Cristina Izzo1, Andrea Airoldi1, Elisa Lazzarich1, Paola Ferragigli1 and Piero Stratta1
1Translational Medicine Amedeo Avogadro University, 2Maggiore della Carità Hospital, Nephrology and Transplantation Novara Italy

Introduction and Aims: Outcomes of patients with lupus nephritis (LN) have been improving due to a variety of reasons and relative contributions are difficult to assess. Methods: We included all patients with biopsy-proven LN followed-up at our center and analysed evolution of epidemiological, clinical, histological features and therapeutic immunosuppressive protocols over the last 4 decades.

Results: We enrolled 130 patients stratified by diagnosis over the following periods: ≤1980, n = 43; >1980≤1990, n = 34; >1990≤2000, n = 33; >2000, n = 20. Age at diagnosis decreased from 30 to 26 years old and the interval between diagnosis of Lupus and that of LN has extended from 1 to 3 years. The mortality rate fell from 41.8% to 0%, parallel decreasing in complications. The proliferative classes remained the most represented (59.2%); the need for dialysis has been dramatically reduced (from 23% to 0%). The most significant therapeutic changes in induction therapy between the first and fourth decade were the increasing use of pulse steroid (ST) (from 0% to 65%), the increasing use of cyclophosphamide (CYCLO) (from 25% to 65%). Cumulative load of oral drugs were sharply reduced: ST decreased from 533 to 269 mg/Kg and CYCLO from 505 to 180 mg/Kg over the first 5 years. Multivariate analysis showed that survival improvement is mainly associated with the youngest age at diagnosis and on more recent historical periods. The renal prognosis was worse in male, age>30 years, renal failure, proliferative classes with indexes of chronicity, while it appeared to improve with induction therapy other than oral STER and with high activity index.

Conclusions: The most important factors which determined improved outcomes of LN over the last 4 decades were a progressively earlier diagnosis (from 30-31 to 26-29 years old) and qualitative/quantitative modifications in therapeutic strategies. Adoption of sequential schedules of aggressive induction and fast tapering of immunosuppression have been crucial to achieve better control of the acute phase and reduced toxicity long-term.
CD68 POSITIVE CELLS IN RENAL BIOPSY PREDICT LONG TERM PROGNOSIS IN Proliferative Lupus Nephritis

Cristiane Bitencourt Dias1, Jin Lee2, Leticia Jorge1, Denise Malheiro2, Rui Toledo Barros3 and Viktoria Woronik3
1Nefrologia Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil, 2Pathologia Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil

Introduction and Aims: Studies in proliferative lupus nephritis (LN) showed that in more severe clinical forms the renal histology showed increase macrophages detected by immunohistochemistry. However no long-term assessment of this data is known. The aim of this study was to describe any relations of renal outcomes with total macrophages (CD68+) expressing in renal biopsy specimens obtained on the diagnosis.

Methods: Forty six newly diagnosed patients with proliferative LN were prospectively followed-up during 3.5 (3.2 - 4.0) years. Conventional laboratory tests were collected on diagnosis and on last follow-up. Renal biopsy was done on diagnosis and immunohistochemical study was performed with monoclonal antibody anti CD68 (DAKO) and macrophages MCP-1 (R&D), and results are expressed as cells/microscopic fields. Patients were stratified in two groups according to renal outcome: GFR ≤ 60 mL/min/1.73m² at the end of follow-up (n=24) and GFR > 60 mL/min/1.73m² (n=22).

Results: Considering all patients (n=46) tubule and interstitial CD68+ cells showed negative correlation with final MDRD (r= -0.3, p=0.01 and r= -0.45, p=0.001). Macrophages MCP-1 interstitial had positive correlation with chronicity index (r=0.4, p=0.0031). Tubule and interstitial CD68+ cells expression on renal biopsies may predict long term GFR in proliferative lupus nephritis.

SP354 USAGE OF CYCLOSPORIN IN LUPUS NEPHRITIS CLASS III, IV AND V – ONE CENTRE EXPERIENCE

Elena V. Zakharova1 and Ekaterina S. Stolyarevich2
1Nephrology City Clinical Hospital n.a. S.P. Botkin Moscow Russian Federation, 2Pathology City Nephrology Center Moscow Russian Federation

Introduction and Aims: Current KDIGO Guidelines for Glomerulonephritis and EULAR/ERA-EDTA Recommendations for Management of Lupus Nephritis suggest cyclosporine (CYC) as an alternative option for initial treatment of lupus nephritis (LN) class V with persistent nephrotic proteinuria, resistant disease not responding to more than one of the recommended initial regimens, and for subsequent treatment of pure class V, or class III/IV intolerant of mycophenolate mofetil and azathioprine (AZA). CYC is also acceptable during pregnancy. We aimed to evaluate retrospectively efficacy of CYC in our cohort of LN patients.

Methods: Using electronic clinical and pathology database we searched 106 LN patients, treated in our nephrology unit since 2002, when we introduced CYC for LN, to 2012. Patients with class I, II and VI, and those who never received CYC were excluded from analysis. Study group included 14 patients, 12 female and 2 male, median age 27.5 [17;39] years. 2 patients had class III, 6 - class IV and 6 - class V LN. Disease duration prior to switching to CYC was 60 [5;168] months, previous treatment included prednisolone in all, cyclophosphamide (CP) “pulses” in 12, mycophenolate mofetil/micophenolic acid (MMF/MPA) in 5, and AZA in 4 cases. Indications for CYC were non-responsiveness or intolerance of CP and MFP/MPA in 6, renal flare after CP and/or MFP/MPA initial and re-induction regimens in 4, and subsequent treatment in 4 patients intolerant of MMF/MPA and AZA. Initial dose of CYC was 200 mg/day [150;250], with dose adjustment to plasma concentration. Duration of therapy constituted 14.5 [1.84] month, duration of follow-up - 18 [1.84] months.

Results: 6 patients (42.8%) achieved and/or sustained complete remission, 6 (42.8%) - partial remission, and only in 2 (14.3%) cases CYC was non-effective. Changes in proteinuria and kidney function and distribution of efficacy in different LN classes are shown in tables 1 and 2.

Mycophenolate Mofetil treatment for resistant lupus nephritis: a single center experience

SP355

Arzu Velgoz1, Derya Guler4, Serdar Naalac1, Gurdal Birdal1, Hakki Arikan1, Mehmet Koc1, Haner Direskeneli2, Serhan Tuglular1 and Cetin Ozener1
1Nephrology Marmara University, School of Medicine Istanbul Turkey, 2Rheumatology Marmara University, School of Medicine Istanbul Turkey

Introduction and Aims: Lupus nephritis (LN) is one of the major complications of systemic lupus erythematosus. Mycophenolate mofetil (MMF) is the prominent treatment for maintenance of remission, prevention of recurrence and progression to chronic renal disease. In our study, we evaluate the long term results of MMF treatment in patients with resistant LN.

Methods: Twenty-seven patients (23 female, four male; mean age 36.5±10.6 years) were included into the study. All patients received induction therapy with cyclophosphamide. SLEDAI scores, creatinine levels, estimated glomeruler filtration rates, 24-hour protein excretions, C3 and C4 levels were collected both at the beginning and the last visit. Patients were compared according to previous maintenance immunosuppressive therapy. The end stage renal disease (ESRD) development and mortality rates were also recorded.

Results: Mycophenolate mofetil (MMF) is the prominent treatment for maintenance of remission, prevention of recurrence and progression to chronic renal disease. In our study, we evaluate the long term results of MMF treatment in patients with resistant LN.

Mycophenolate Mofetil Treatment for Resistant Lupus Nephritis: A Single Center Experience

SP333

GFR > 60mL/min/1.73m² (n=22)
GFR ≤ 60mL/min/1.73m² (n=24)

| Age (years) | 24.4 ± 7.2 | 25.5 ± 7.2 | ns |
| Gender (F/M) | 21 / 1 | 21 / 3 | ns |
| Activity Index (renal biopsy) | 5.0 ± 1.5 | 4.1 ± 2.1 | ns |
| Chronicity Index (renal biopsy) | 2.0 ± 2.1 | 4.0 ± 2.1 | 0.01 |
| Initial GFR – MDRD (ml/min/1.73m²) | 58.1 ± 37.1 | 35.1 ± 24.9 | 0.01 |
| Initial Proteinuria (g/day) | 4.0 ± 2.7 | 4.4 ± 2.8 | ns |
| Initial C3 complement (mg/dL) | 53.3 ± 28.4 | 50.4 ± 16.6 | ns |
| Initial C4 complement (mg/dL) | 5.5 (4.5-8.0) | 8.0 (6.0-11.5) | ns |
| Last GFR – MDRD (ml/min/1.73m²) | 93.0 (78.0-116.5) | 10.5 (6.0-46.) | <0.0001 |
| Last Proteinuria (g/day) | 0.6 ± 0.7 | 1.7 ± 1.7 | 0.008 |
| CD68+ cells tubule /field | 2.0 (0.8-30.0) | 6.4 (1.9-11.8) | 0.0064 |
| CD68+ cells Interstitial /field | 4.9 (3.2-9.0) | 36.2 (10.1-101.4) | 0.0003 |
| CD68+ cells glomerulos/field | 5.1 (2.9-11.6) | 6.7 (3.0-20.0) | ns |
| Macrophages MCP1 tubule /field | 0.1 (0-0.39) | 0.2 (0.8-0.65) | ns |
| Macrophages MCP1 interstitial /field | 5.7 (1.2-12.5) | 12.6 (3.6-105.5) | 0.03 |

| Patient | Before CYC | At last evaluation | P value |
| Medican proteinuria g/day | 2.6 (0.15;15.0) | 0.3 (0.05;5.5) | <0.05 |
| Medican creatinine µmol/l | 102 (68;300) | 100 (74;441) | NS |

Table 1. Influence of CYC on proteinuria and kidney function

Table 2. Results of CYC treatment in different LN classes

In one LN class V after 5 years of treatment with sustained partial remission 2 nd kidney biopsy did not show any signs of CYC-toxicity. 3 patients had normal pregnancies and delivered healthy babies, in 1 case after delivery developed renal flare, successfully treated with MMF. There were no other flares in patients treated with CYC.

Conclusions: In our cohort of 106 LN patients 13% were treated with CYC. In 85.6% of cases complete or partial remissions were achieved/sustained with lowering of median proteinuria from 1.6 to 0.3 g/day and nicely preserved kidney function. The best results were seen in LN class V (100% of remissions, mostly complete), the worst - in class IV (only 66.6% of remissions, mostly partial).

Nephropathy Dialysis Transplantation

Abstracts

Volume 28 | Supplement 1 | May 2013

doi:10.1093/ndt/gft113 | i183
patients regarding to previous treatment. The mean follow-up time was 50.5 months. One patient died due to sepsis. ESRD was developed in three patients.

Conclusions: MMF treatment has provided an improvement in SLEDAI score and proteinuria in resistant LN patients. There was no deterioration in renal function. MMF is an ideal treatment for patients who were not on complete remission after induction therapy with cyclophosphamide.

### Random Spot Urine Protein/Creatinine Ratio: A Reliable Method for Monitoring Lupus Nephritis?

Maria Guedes Marques, Patricia Cotovio, Francisco Ferrer, Cristina Silva, Carlos Boteho, Karina Lopes, Pedro Maia, Armando Carreira and Marco Caamaño

1 Nephrology Centro Hospitalar Universitário de Coimbra - Hospital Geral Coimbra Portugal, 2 Nephrology Centro Hospitalar Universitário de Coimbra - HUC Coimbra Portugal

**Introduction and Aims:** Lupus nephritis (LN) is a common and severe manifestation of Systemic Lupus Erythematosus (SLE) that can lead to End Stage Renal Disease (ESRD) and death. There have been numerous reports on the use of random spot urine protein/creatinine (P/C) ratio to estimate 24-hour proteinuria in non-SLE Chronic Kidney Disease (CKD). However, few papers have been published regarding SLE patients and some of those authors wrote that random spot urine P/C ratio is unreliable to monitoring proteinuria in SLE GN patients. According to Kidney Disease Outcomes Global Improving (KDIGO) clinical practice Guidelines for Glomerulonephritis, random spot urine P/C ratio should be used for monitoring LN. The aim of our study was to evaluate the agreement of urine P/C ratio in untimed specimens with proteinuria measured by 24 h urinary collection in patients with SLE.

**Methods:** A prospective observational study was performed. A total of 53 paired (106) spot and 24-hour urine collections were evaluated, as part of routine monitoring of their disease activities. Statistical analyze was performed by SPSS 20.0 Statistical Analysis.

**Results:** Paired-samples T test didn’t revealed significant differences between the two assay methods (p = 0.216) and a statistically significant correlation was observed between them: Pearson coefficient 0.847 (p < 0.001). After stratifying by degrees of proteinuria, the correlation between 24-hour proteinuria and P/C ratio was maintained in the proteinuria range lower than 500mg/24h (Pearson 0.471, p = 0.006) and above 1000mg/24h (Pearson 0.917, p = 0.010), but this correlation was not observed between 500 and 1000mg/24h (Pearson -0.106, p = 0.718). When stratifying according to background of LN, paired-samples T test didn’t revealed significant differences between the groups.

**Conclusions:** Our study demonstrated a negative, not significant, correlation between urine P/C ratio and 24 h proteinuria for a range of 500 to 1000mg/24h. This finding is of greater importance and concern because this range is quite common among patients with LN in remission, in whom it is essential to monitor and detect renal flares early. Until further clarification, to the best of our knowledge, we maintain reluctant to completely substitute the 24-hour collection by P/C ratio especially when (according to other activity parameters) a renal flare is suspected; as well as, before any change in therapy.